We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Kochujang, a Fermented Soybean-based Red Pepper Paste, Decreases Visceral Fat and Improves Blood Lipid Profiles in Overweight Adults

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01532375
Recruitment Status : Completed
First Posted : February 14, 2012
Last Update Posted : February 14, 2012
Information provided by:
Chonbuk National University Hospital

Brief Summary:
With the epidemic of obesity and diabetes growing around the world, Kochujang (KCJ) may be potentially effective in preventing and treating obesity and cardiovascular risks if proven in humans. However, human trial still have not been reported with KCJ supplementation. In the present study, we investigated the hypothesis that KCJ supplementation can be decrease the body fat and improve blood lipid profiles in overweight adults.

Condition or disease Intervention/treatment Phase
Overweight Dietary Supplement: Kochujang Dietary Supplement: placebo Phase 2

Detailed Description:

The aim of this study was to evaluate the efficacy of KCJ supplementation on anthropometric parameters, visceral fat/subcutaneous fat, and blood lipid profiles in overweight subjects.

Sixty overweight subjects with BMI >25 kg/m2 and waist-hip-ratio (WHR) ≥ 0.90 for men and ≥ 0.85 for women were randomly assigned to either KCJ supplement (n=30, 32 g/day) or placebo (n=30, 32 g/day) group for 12 weeks.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 60 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Prevention
Official Title: Kochujang Decreases Visceral Fat and Improves Lipids Profiles
Study Start Date : October 2009
Actual Primary Completion Date : March 2010
Actual Study Completion Date : March 2010

Arm Intervention/treatment
Experimental: Kochujang(32g) Dietary Supplement: Kochujang
Kochujang (32g/day) for 12weeks.

Placebo Comparator: placebo(32g) Dietary Supplement: placebo
placebo(32g/day) for 12weeks

Primary Outcome Measures :
  1. Visceral fat [ Time Frame: after 12 weeks of consumption ]

Secondary Outcome Measures :
  1. Body Mass Index [ Time Frame: after 12 weeks of consumption ]
  2. Subcutaneous fat [ Time Frame: after 12weeks ]
  3. Triglyceride [ Time Frame: after 12week of consumption ]
  4. Atherosclerosis index [ Time Frame: after 12weeks of consumption ]
  5. Apolipoprotein [ Time Frame: after 12weeks of consumption ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   19 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • BMI >25kg/m2 and 2)Waist-Hip Ratio (WHR): WHR> 0.90(male), WHR>0.85(female)

Exclusion Criteria:

  • lipid metabolic disorders
  • >10% changes in body weight in the past 3 months
  • Cardiovascular disease such as arrhythmia, heart failure, myocardial infarction, and wearing pacemaker
  • Allergy or hypersensitivity to any of the ingredients in the test products - History of reaction to any of the experimental products or of gastrointestinal diseases such as Crohn's disease or gastrointestinal surgery
  • Participation in other clinical trials within the past 2 months
  • Abnormal hepatic liver function, renal disease such as acute

    • chronic renal failure, nephrotic syndrome
  • Use of anti-psychosis drug therapy within 2 months
  • Laboratory test, medical or psychological conditions deemed by the investigators to interfere with successful participation in the study
  • History of alcohol or substance abuse
  • Pregnancy or breastfeeding

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01532375

Sponsors and Collaborators
Chonbuk National University Hospital
Layout table for investigator information
Study Chair: Soo-Wan Chae, Ph.D, MD Chonbuk National University Hospital
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
ClinicalTrials.gov Identifier: NCT01532375    
Other Study ID Numbers: CUH_2008_AT_4
First Posted: February 14, 2012    Key Record Dates
Last Update Posted: February 14, 2012
Last Verified: February 2012
Keywords provided by Chonbuk National University Hospital:
visceral fat
Additional relevant MeSH terms:
Layout table for MeSH terms
Body Weight